Hot Tour Summer Sees Taylor, Beyonce Eye $1 bn Mark

Taylor Swift performs onstage on the first night of her 'Eras Tour' at AT&T Stadium in Arlington, Texas in March 2023. SUZANNE CORDEIRO / AFP/File
Taylor Swift performs onstage on the first night of her 'Eras Tour' at AT&T Stadium in Arlington, Texas in March 2023. SUZANNE CORDEIRO / AFP/File
TT

Hot Tour Summer Sees Taylor, Beyonce Eye $1 bn Mark

Taylor Swift performs onstage on the first night of her 'Eras Tour' at AT&T Stadium in Arlington, Texas in March 2023. SUZANNE CORDEIRO / AFP/File
Taylor Swift performs onstage on the first night of her 'Eras Tour' at AT&T Stadium in Arlington, Texas in March 2023. SUZANNE CORDEIRO / AFP/File

It's a pop queen's world and we're just living in it: Industry watchers are speculating over whether Tay or Bey could post the first billion-dollar tour, as 2023 witnesses an explosion of shows.

Taylor Swift and Beyonce are among the dozens of stars who've hit the road and fueled a booming arena market, as demand for live entertainment soars after years of pandemic-induced cancellations and postponements.

From Pink to Coldplay, Bruce Springsteen to Drake, and SZA to The Weeknd, stadiums across the United States and beyond are setting the stage for what's poised to be the biggest year for live music on record.

"I have never seen as many artists out at the same time, in the same space," Stacy Merida, a professor at American University who studies the business of music, told AFP.

Madonna -- who in the early 1990s created the contemporary tour as we know it, with elaborate sets and costumes -- was set to embark on a career-spanning tour in mid-July, but postponed it due to illness.

The 64-year-old is slated to start her European leg of shows in October, and reschedule the North American concerts for later dates.

So it's the 33-year-old Swift who is now within striking distance of the billion-dollar mark, with 106 current dates on her "Eras" tour.

Odds are also favoring Beyonce as she commences the North American leg of her "Renaissance" tour.

If either cross the history-making line, they'd jump past Elton John.

His just-ended "Farewell Yellow Brick Road" tour, which began in 2018, had grossed more than $910 million as of June 18, a few weeks before his final show in Stockholm on July 8, according to Billboard Boxscore.

John had surpassed the previous record-holder, Ed Sheeran's 2017-2019 "Divide" tour, which nabbed $776 million.

Part of the current boom comes from increased ticket prices: Sheeran charged just under $100 for "Divide," according to tracker Pollstar, but played well over 200 shows.

Tickets for Bey and Tay are averaging out to be more than double that, for basic seats.

Live Nation, which in 2010 merged with Ticketmaster, says it's already sold 100 million tickets for 2023 concerts -- more than it sold for the entire year of 2019.

The company posted $4.4 billion in revenue during this year's second quarter, promoting some 12,500 concerts to 33.5 million fans.

"With most of the world fully re-opened, it's clear that concerts remain a high priority for fans," Live Nation said in its most recent earnings report.

Ticketing grumbles
But while demand has soared, it's not without much grumbling over the privileged position of Live Nation and Ticketmaster.

For years, concertgoers have complained of hidden fees, soaring costs, rampant scalpers and limited tickets due to presales.

The issue reignited earlier this year after botched sales for Swift's tour wreaked havoc, prompting a congressional hearing over purported anti-competitive practices and ardent calls for the company to be broken up.

That possibility doesn't appear on the horizon, and ticket prices keep climbing in the meantime -- and fans keep paying.

"The vertical integrated monopoly really has a lot of ripple effects in terms of prices," said Andrew Leff, a music industry veteran and attorney who teaches at the University of Southern California.

"If you're Ticketmaster and you can charge anything you want and you don't have any competition, and a demand for Taylor Swift or Beyonce comes along, that's simple supply-and-demand economics," he told AFP.

"They can charge whatever they want -- which is what they do."

'Beyonce blip'
And according to Leff, the concert boom isn't necessarily seeing its benefits trickle down to smaller acts.

"There's really two music industries," he said. "There's the music industry for the one percent and the music industry for the 99 percent."

"Unless you're playing in front of 500 people or more every night, you're probably not even breaking even."

It's an all too familiar story: Touring doesn't come cheap, and it's a lifeline for artists whose royalties from streaming notoriously make the tiniest of dents.

But with everyone back on the road trying to make up lost revenue from the pandemic years, there's competition for everything from venues to tour buses.

Last fall, the indie artist Santigold was among the first to speak out on the challenges facing performers like her -- and canceled her tour, saying she was "simply unable to make it work," not least due to inflation and competition in a saturated market.

Meanwhile, recent data from research company QuestionPro suggests Swift's tour could generate some $4.6 billion in consumer spending in the United States alone, pumping dollars into local economies including hotels and restaurants.

And Queen Bey's "Renaissance" tour caused a "Beyonce blip" when she performed in Stockholm in May, driving up Sweden's inflation by about 0.2 percentage points.

"Beyonce's start of her world tour in Sweden seems to have colored May inflation," said Michael Grahn, chief economist for Sweden at Danske Bank, at the time.



Doctor Charged in Connection with Matthew Perry’s Death to Appear in Court After Plea Deal 

Actor Matthew Perry poses at the CBS Studios rooftop summer soiree in West Hollywood, California May 18, 2015. (Reuters)
Actor Matthew Perry poses at the CBS Studios rooftop summer soiree in West Hollywood, California May 18, 2015. (Reuters)
TT

Doctor Charged in Connection with Matthew Perry’s Death to Appear in Court After Plea Deal 

Actor Matthew Perry poses at the CBS Studios rooftop summer soiree in West Hollywood, California May 18, 2015. (Reuters)
Actor Matthew Perry poses at the CBS Studios rooftop summer soiree in West Hollywood, California May 18, 2015. (Reuters)

One of two doctors charged in connection with Matthew Perry's death is set to appear Friday in a federal court in Los Angeles, where he is expected to plead guilty to conspiring to distribute the surgical anesthetic ketamine.

Dr. Mark Chavez, 54, of San Diego, reached a plea agreement with prosecutors earlier this month and would be the third person to plead guilty in the aftermath of the “Friends” star’s fatal overdose last year.

Chavez agreed to cooperate with prosecutors as they pursue others, including the doctor Chavez worked with to sell ketamine to Perry. Also working with the US Attorney's Office are Perry’s assistant, who admitted to helping him obtain and inject ketamine, and a Perry acquaintance, who admitted to acting as a drug messenger and middleman.

The three are helping prosecutors as they go after their main targets: Dr. Salvador Plasencia, charged with illegally selling ketamine to Perry in the month before his death, and Jasveen Sangha, a woman who authorities say is a dealer who sold the actor the lethal dose of ketamine. Both have pleaded not guilty and are awaiting trial.

Chavez admitted in his plea agreement that he obtained ketamine from his former clinic and from a wholesale distributor where he submitted a fraudulent prescription.

After a guilty plea, he could get up to 10 years in prison when he is sentenced.

Perry was found dead by his assistant on Oct. 28. The medical examiner ruled ketamine was the primary cause of death. The actor had been using the drug through his regular doctor in a legal but off-label treatment for depression that has become increasingly common.

Seeking more ketamine than his doctor would give him, about a month before his death Perry found Plasencia, who in turn asked Chavez to obtain the drug for him.

“I wonder how much this moron will pay,” Plasencia texted Chavez. The two met up the same day in Costa Mesa, halfway between Los Angeles and San Diego, and exchanged at least four vials of ketamine.

After selling the drugs to Perry for $4,500, Plasencia asked Chavez if he could keep supplying them so they could become Perry’s “go-to.”

US Attorney Martin Estrada said in announcing the charges on Aug. 15 that “the doctors preyed on Perry’s history of addiction in the final months of his life last year to provide him with ketamine in amounts they knew were dangerous.”

Plasencia is charged with seven counts of distribution of ketamine and two charges related to allegations he falsified records after Perry’s death. He and Sangha are scheduled to return to court next week. They have separate trial dates set for October, but prosecutors are seeking a single trial that likely would be delayed to next year.

Perry struggled with addiction for years, dating back to his time on “Friends,” when he became one of the biggest stars of his generation as Chandler Bing. He starred alongside Jennifer Aniston, Courteney Cox, Lisa Kudrow, Matt LeBlanc and David Schwimmer for 10 seasons from 1994 to 2004 on NBC’s megahit sitcom.